TY - JOUR
T1 - Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders
AU - Inbal, A.
AU - Epstein, O.
AU - Blickstein, D.
AU - Kornbrot, N.
AU - Brenner, B.
AU - Martinowitz, U.
PY - 1993
Y1 - 1993
N2 - Haemostatic efficacy and pharmacokinetic analysis of solvent/detergent (S/D) treated, virus inactivated plasma (Octaplas®, Germany) was evaluated in eight patients with hereditary factor VII, X and XI deficiency and in three patients with acquired coagulation disorders due to liver disease. The patients received the S/D plasma for treatment of haemarthrosis, menorrhagia or before surgical procedures. In all the patients the S/D plasma was sufficient to prevent or stop bleeding. Side effects included urticaria (one patient) and moderate anaphylactoid reaction (one patient). No evidence of plasma-born viral infections was observed up to 12 months after the treatment (95% confidence limits 0-22%). Calculated mean half-life of coagulation factors VII, X and XI was 4.36 h, 49.21 h and 44.5 h, respectively, similar to that observed with fresh-frozen plasma. Because of retained coagulation factor integrity and improved viral safety, S/D plasma could be considered a superior alternative to standard fresh-frozen plasma.
AB - Haemostatic efficacy and pharmacokinetic analysis of solvent/detergent (S/D) treated, virus inactivated plasma (Octaplas®, Germany) was evaluated in eight patients with hereditary factor VII, X and XI deficiency and in three patients with acquired coagulation disorders due to liver disease. The patients received the S/D plasma for treatment of haemarthrosis, menorrhagia or before surgical procedures. In all the patients the S/D plasma was sufficient to prevent or stop bleeding. Side effects included urticaria (one patient) and moderate anaphylactoid reaction (one patient). No evidence of plasma-born viral infections was observed up to 12 months after the treatment (95% confidence limits 0-22%). Calculated mean half-life of coagulation factors VII, X and XI was 4.36 h, 49.21 h and 44.5 h, respectively, similar to that observed with fresh-frozen plasma. Because of retained coagulation factor integrity and improved viral safety, S/D plasma could be considered a superior alternative to standard fresh-frozen plasma.
KW - coagulation factor deficiency
KW - efficacy
KW - solvent/detergent fresh frozen plasma
UR - http://www.scopus.com/inward/record.url?scp=0027326230&partnerID=8YFLogxK
U2 - 10.1097/00001721-199308000-00011
DO - 10.1097/00001721-199308000-00011
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 8218857
AN - SCOPUS:0027326230
SN - 0957-5235
VL - 4
SP - 599
EP - 604
JO - Blood Coagulation and Fibrinolysis
JF - Blood Coagulation and Fibrinolysis
IS - 4
ER -